Genprex (GNPX) Cash from Investing Activities (2016 - 2024)
Genprex (GNPX) posted quarterly Cash from Investing Activities of -$1.0 for Q4 2024, up 99.99% year-over-year from -$0.5 in Q1 2024, and down 100.0% quarter-over-quarter from $790467.0 in Q2 2024.
Genprex (GNPX) Cash from Investing Activities (2016 - 2024) Analysis & Trends
Genprex's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$1.0 for Q4 2024.
- In Q4 2024, Cash from Investing Activities rose 99.99% year-over-year to -$1.0; the TTM figure through Sep 2025 stood at -$1.0 (down 100.0% YoY), while the FY2024 annual figure was $774644.0, up 1187.77% from the prior year.
- Cash from Investing Activities for Q4 2024 stood at -$1.0, down from $790467.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $790467.0 in Q2 2024, with the low at -$2.3 million in Q4 2020.
- The 5-year median for Cash from Investing Activities is -$16048.0 (2022), against an average of -$93544.8.
- The sharpest annual moves came in 2020 and 2024: Cash from Investing Activities sank 2451.75% in 2020, then soared 4052.34% in 2024.
- Genprex's Cash from Investing Activities stood at -$2.3 million in 2020, then jumped by 92.59% to -$173577.0 in 2021, then surged by 88.48% to -$19998.0 in 2022, then soared by 50.84% to -$9831.0 in 2023, then soared by 99.99% to -$1.0 in 2024.
- Business Quant data shows GNPX's Cash from Investing Activities at -$1.0 in Q4 2024, $790467.0 in Q2 2024, and -$15822.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Genprex | 1.88 Mn | -13.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1.00 |
| Dec 31, 2024 | -1.00 |
| Jun 30, 2024 | 790,467.00 |
| Jun 30, 2024 | 790,467.00 |
| Mar 31, 2024 | -15,822.00 |
| Mar 31, 2024 | -15,822.00 |
| Dec 31, 2023 | -9,831.00 |
| Dec 31, 2023 | -9,831.00 |
| Sep 30, 2023 | -21,756.00 |
| Sep 30, 2023 | -21,756.00 |
| Jun 30, 2023 | -20,000.00 |
| Jun 30, 2023 | -20,000.00 |
| Mar 31, 2023 | -19,627.00 |
| Mar 31, 2023 | -19,627.00 |
| Dec 31, 2022 | -19,998.00 |
| Dec 31, 2022 | -19,998.00 |
| Sep 30, 2022 | -16,048.00 |
| Sep 30, 2022 | -16,048.00 |
| Jun 30, 2022 | -21,848.00 |
| Jun 30, 2022 | -21,848.00 |